Cargando…

Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade

Detalles Bibliográficos
Autores principales:	Yong, Kok Pin, Kim, Ho Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674934/ https://www.ncbi.nlm.nih.gov/pubmed/34911792 http://dx.doi.org/10.1212/NXI.0000000000001110

Ejemplares similares

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
por: Fragoso, Diego Cardoso, et al.
Publicado: (2023)

NMOSD and MOGAD Dual Positivity: An Extremely Rare Phenomenon
por: Agarwal, Ayush, et al.
Publicado: (2022)

Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2
por: Graf, Jonas, et al.
Publicado: (2020)

Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1
por: Graf, Jonas, et al.
Publicado: (2020)

Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
por: Derdelinckx, Judith, et al.
Publicado: (2021)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD
por: Kim, Sohyeon, et al.
Publicado: (2023)

The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
por: Sen, Sedat, et al.
Publicado: (2022)

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD
por: Lin, Liuyu, et al.
Publicado: (2022)

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies
por: Asseyer, Susanna, et al.
Publicado: (2020)

COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD
por: Yeo, Tianrong, et al.
Publicado: (2022)

The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis
por: Roca-Fernández, A, et al.
Publicado: (2021)

Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) und Anti-Myelin-Oligodendrozyten-Glykoprotein-Antikörper-assoziierte Erkrankungen (MOGAD)
por: Seifert-Held, Thomas
Publicado: (2022)

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
por: Dinoto, Alessandro, et al.
Publicado: (2022)

New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD
por: Takeshita, Yukio, et al.
Publicado: (2021)

Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina
por: Contentti, Edgar Carnero, et al.
Publicado: (2021)

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
por: Schroeder-Castagno, Maria, et al.
Publicado: (2022)

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
por: Fadda, Giulia, et al.
Publicado: (2022)

COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore
por: Yeo, Tianrong, et al.
Publicado: (2023)

Demystifying the Publication Process
por: Zelmer, Jennifer
Publicado: (2017)

Demystifying the Enigmatic Fibroblast in Pulmonary Fibrosis
por: Zhou, Yong, et al.
Publicado: (2023)

Paroxysmal sneezing in NMOSD: Further evidence of the localization of the human sneeze center
por: López-Chiriboga, A. Sebastian, et al.
Publicado: (2016)

The Second Law and Entropy Misconceptions Demystified
por: Kostic, Milivoje M.
Publicado: (2020)

Plasmapheresis for NMOSD: Not a Rescue Therapy Anymore!?
por: Bhatia, Rohit, et al.
Publicado: (2019)

Helicobacter pylori infection may influence prevalence and disease course in myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD) similar to MS but not AQP4-IgG associated NMOSD
por: Malli, Chaithra, et al.
Publicado: (2023)

Microbiome, demystifying the role of microbial communities in the biosphere
por: Wommack, K Eric, et al.
Publicado: (2013)

Submission to Publication Demystified: A Guide for Authors
por: Dhammi, Ish Kumar, et al.
Publicado: (2017)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

A 10-Year Single-Center Study of the Clinical Characteristics of Optic Neuritis-Related NMOSD, MS, and Double Seronegative Optic Neuritis, Together with Factors Predicting Visual Outcomes
por: Kemchoknatee, Parinee, et al.
Publicado: (2023)

Clinical and neuroimaging findings in MOGAD–MRI and OCT
por: Bartels, Frederik, et al.
Publicado: (2021)

Attack phenotypes and disease course in pediatric MOGAD
por: Santoro, Jonathan D., et al.
Publicado: (2023)

Editorial: MOGAD, current knowledge and future trends
por: Siritho, Sasitorn, et al.
Publicado: (2023)

Demystifying the NIH Grant Application Process: The Rest of the Story
por: Horner, Ronnie D.
Publicado: (2007)

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD
por: Shi, Mingchao, et al.
Publicado: (2022)

Demystifying Bitter Taste Receptor Relaxation of Airway Smooth Muscle
por: Tang, Dale D.
Publicado: (2023)

MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity
por: Yandamuri, Soumya S., et al.
Publicado: (2023)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

Forex demystified
por: Borman, David
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mijgvnr6oiqjkjlemudalpa1d1